721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study

Publication | Closed Access

DOI

Citations

References

2021

Year

N. Colombo, Dorothy Nguyen, Gini F. Fleming, Rachel N. Grisham, Domenica Lorusso, Toon Van Gorp, Ana Oaknin, H.I. Pashova, Andreas Grauer

Annals of Oncology

MedicinePharmacologyPhase Ii StudyGynecologyCancer TreatmentOncologyEndocrine-related CancerOvarian Cancer